<DOC>
	<DOC>NCT00936156</DOC>
	<brief_summary>Primary objective : To increase the 3 year progression-free survival from 40% to 60%. Patients included : metastatic, cerebral primitive neuroectodermal tumors in children aged over 5 years.</brief_summary>
	<brief_title>Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years</brief_title>
	<detailed_description />
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>1. Type of tumor: Metastatic medulloblastoma whatever the quality of the initial resection (radiologically visible metastases by MRI and/or CSF invaded by at least one mass of tumoral cells). Incompletely resected local medulloblastoma with a residue &gt; 1.5 cm2. Anaplastic, large cell medulloblastoma whatever the risk criteria (localized or metastatic, complete or incomplete resection). Medulloblastoma with amplification of cmyc or Nmyc whatever the risk criteria (local or metastatic, complete or incomplete resection). Local and/or metastatic sustentorial PNET. 2. Age at diagnosis of the medulloblastoma of more than 5 years and less than 20 years. 3. Age at diagnosis of SPNET of more than 10 years and less than 20 years. 4. Nutritional and general status compatible with treatment, Lansky score &gt; 60. 5. Estimated life expectancy &gt; 1 months. 6. Radiographs must be available for the second reading in dicom format on a CDROM. 7. Hematological function at diagnosis: PMN &gt; 1.0 x 109/l and platelets &gt; 100 x 109/l. 8. Hepatic function at diagnosis: serum bilirubin &lt; 1.5 times normal value; ASAT and ALAT &lt; 2.5 times normal values; prothrombin time &gt; 50%; fibrinogen &gt; 1.5 g/l. 9. Renal function at diagnosis: serum creatinine according to age in a correctly hydrated child: 1 to 15 years &lt; 65 micromol/l; 15 to 18 years &lt; 110 micromol/l. 10. No organ toxicity (Grade &gt; 2 according to NCICTC coding, version 2.0) 11. No other concomitant anticancer treatment. 12. No prior anticancer therapy. 13. No prior irradiation. 14. Written informed consent signed by both parents or legal guardians 1. Failure to comply with one of the inclusion criteria. 2. Severe or lifethreatening infection. 3. Uncontrolled active or symptomatic intracranial hypertension. 4. Refusal of parents or legal guardian. 5. Patients incapable of undergoing medical followup for geographical, social or mental reasons</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>